Shire Touts Ongoing Xiidra Growth, Targets Increased Medicare Access
Company outlines manufacturing streamlining and efficiency effort that it expects to add significant cost savings above synergies anticipated from merger with Baxalta.
You may also be interested in...
Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending arrival of a generic Restasis throws a curveball into the whole category.
Shire had a combined 17 manufacturing plants after the Baxalta merger, but plans to cut that to a total of 12. Manufacturing issues hit sales of its HAE drug Cinryze in the third quarter, and the firm is losing Lialda sales faster than expected.
Allergan's Medicare Part D contracting tactics for Restasis have blocked Xiidra from the market, Shire lawsuit claims.